About: Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 12 May 2012

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articol științific (ro) articolo scientifico (it) artigo científico (gl) artigo científico (pt) artigo científico (pt-br) artikull shkencor (sq) artículo científico (es) bilimsel makale (tr) scienca artikolo (eo) vedecký článok (sk) vetenskaplig artikel (sv) vitenskapelig artikkel (nb) vitskapeleg artikkel (nn) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научная статья (ru) научни чланак (sr) מאמר מדעי (he) artikel ilmiah (id) article scientifique (fr) বৈজ্ঞানিক নিবন্ধ (bn) artículu científicu espublizáu en 2012 (ast) наукова стаття, опублікована в травні 2012 (uk) 2012 թվականի մայիսի 12-ին հրատարակված գիտական հոդված (hy) scientific article published on 12 May 2012 (en) scientific article published on 12 May 2012 (en-ca) scientific article published on 12 May 2012 (en-gb) مقالة علمية نشرت في 12 مايو 2012 (ar)
publication date	wds:Q38009942-F3A8EA9C-057E-43E6-AE4E-18C1B0F15BAA
publication date	2012-05-12 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q38009942-B860D5B7-44D7-4590-A001-B6B6F0EB3E22
language of work or name	English
cites work	wds:Q38009942-1A1B9970-E276-4E6B-9EA8-76D104E6BDDD wds:Q38009942-21F5535B-4648-439E-BDFF-19B3E5683308 wds:Q38009942-264F8A49-7D26-402B-9019-1055CD71D939 wds:Q38009942-28975D63-7050-4D50-90CC-1D97C3B2C156 wds:Q38009942-30D13126-266C-4878-AECF-3858B7FA54C3 wds:Q38009942-31E05D47-152D-44AD-98DD-07648B0E5A0C wds:Q38009942-392CDC3C-66A1-4D8C-BB6E-B070F90FD71A wds:Q38009942-64ABA23D-9359-41D7-8F2C-3EFB3851495E wds:Q38009942-680CBF86-A1B8-408D-9B40-B88D06BFCE8E wds:Q38009942-6A40BA35-108A-4788-8DF3-FC381FACF379 wds:Q38009942-7F5296D5-F85F-4FFB-9D8E-39993661BB93 wds:Q38009942-8C2DC046-9F9E-4C09-8A5F-236F69D043DE wds:Q38009942-9ED8D2A3-585A-4A31-A1FF-3353F8C60D16 wds:Q38009942-B22429DE-4D29-4B55-8737-15442256E7C4 wds:Q38009942-C0C274B5-BBF3-42B5-89FC-8F4793699B3C wds:Q38009942-CE37CCC2-B6FC-41FA-8F04-4AD3A5C492C6 wds:Q38009942-DCA955B8-5F1D-448E-85AB-AA6885C0E597 wds:Q38009942-DF240607-6C33-44B9-AEA6-AF44837E2DCB wds:Q38009942-EEF2AF39-FCB8-4DEF-9F4B-73345F23D0AC
cites work	Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer Sipuleucel-T immunotherapy for castration-resistant prostate cancer New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade Expression of endothelin receptor a associated with prostate cancer progression Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer Beyond PSA: utility of novel tumor markers in the setting of elevated PSA. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double- New molecular targets in bone metastases. Updates on therapeutic targets and agents in castration-resistant prostate cancer.
author name string	wds:Q38009942-10F15153-7C47-49B9-A1F3-0D1A031D9BF7 wds:Q38009942-16AD8481-CEFB-4BFD-ABA7-13A1B7AB96B9 wds:Q38009942-3337A52F-B036-4FC4-8266-88FF52F6EC3A wds:Q38009942-380BAF25-FFC8-45A4-95D5-BF47ED82205B wds:Q38009942-6F2BE119-16BE-4EB9-8927-11ABDAA58CD5 wds:Q38009942-D6A9F305-9D53-4A60-B6F0-82C6E6DF2CB0 wds:Q38009942-F6BB675D-D801-416F-9702-2A151A9F5319
author name string	Martin Gleave Kurt Miller Evan Y Yu Celestia S Higano Joel Nelson Judd W Moul Faith E Nathan
rdfs:label	Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer (en) Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer (nl) Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer (ast)
skos:prefLabel	Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer (en) Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer (nl) Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer (ast)
name	Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer (en) Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer (nl) Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer (ast)
author	wds:Q38009942-3FD4A26F-040C-4EF0-9DD0-D5F48B93C2CC
author	Karim Fizazi
title	wds:Q38009942-1765F445-F4E6-41F8-8A6B-D03359EF3B95

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software